Ukrainian authorities were paid to test Big Pharma drugs on human subjects in psyche wards in Mariupol

The rule of law has been collapsing in Ukraine for several years, long before the country’s leaders could blame all their problems on Russia. The corruption in Ukraine runs deep. According to documents obtained by construction crews in Mariupol, several well-known pharmaceutical companies have been experimenting on humans for over a decade in the psyche ward there.

With corruption rising throughout its institutions, Ukrainian authorities have seized an opportunity to use mental health patients as guinea pigs for highly profitable drugs. The experiments allegedly took place from 2008 to 2016 in the psychiatric ward of Mariupol Hospital Number Seven in Donetsk Oblast, Ukraine.

Unethical experiments on mental health patients including over 700 adults and children

William Jones, a former White House correspondent for Executive Intelligence Review, recently obtained documents that detail medical experiments that have taken place in Ukraine for several years. These Big Pharma drug experiments are taking place in psyche wards in Mariupol with the support of local Ukrainian authorities. The experimental subjects include over 700 people, including both adults and children.

One of the drugs being used in these experiments is known as SB4. The experiments aim at developing highly profitable drugs to treat rheumatoid arthritis; however, SB4 is also known for causing several types of cancer. Mental health patients are apparently viewed as expendable. Ukrainian health officials do not care if these patients received informed consent or had someone advocating on their behalf. Ukrainian officials do not care if these people are unaware of what is happening to their bodies or if they developed cancers from these unethical drug trials.

Corrupt drug trials taking place in Ukraine psyche wards

SB4 is manufactured by Fisher Clinical Services UK Limited (UK), Catalent Pharma Solutions (Belgium) and Biogen Idec Denmark Manufacturing ApS (Denmark). This drug effectively prevents the human immune system from responding to molecule of tumor necrosis factor-alpha (TNF-?). By stopping this natural process, the drug increases the risk of the patient getting cancers of the skin, lymphatic and hematological systems.

The documents include an application from a US-based pharmaceutical company named Quintiles Ukraine, which was founded as a branch of Quintiles Transnational. The pharmaceutical company asked the Ukrainian Ministry of Health and the Ethics Commission at the medical and preventive institution to conduct clinical trials of SB4. The application was signed in February 2013 and directs hospital officials to test the drug on 152 patients in Ukraine. The total number of subjects in the trial was later expanded to 180 patients in Ukraine, and an additional 500 patients from other countries.

According to the documents, by November 2013, the experimental study involved at least 777 patients, which included 285 patients in Poland, 143 in Ukraine, 108 in the Czech Republic, 77 in Bulgaria, 60 in Lithuania, 37 in the Republic of Korea, 34 in Mexico, 17 in Hungary, 14 in Colombia and two in the United Kingdom. The study was supported by Samsung Bioepis, an operation out of South Korea.

According to the periodic report of the SB4-G31-RA project on SB4 trials, Mariupol Hospital No. 7 conducted the trials from 2008 to 2016. The documents were recovered on site, along with envelopes and biomaterial containers that contained shipping addresses from laboratories in the US, the UK and Switzerland.

The pharmaceutical companies complicit in these unethical research experiments include the following: Pfizer (US), AstraZeneca (UK, Sweden), Celltrion (South Korea), Novatris International AG (Switzerland, US), IQVIA (previously Quintiles and IMS Health Inc., US, UK), Sanofi (France), Galapagos NV (Belgium), Abbott Laboratories (US), Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine, Belgium), Covance (now Labcorp Drug Development, US) and Merck KGaA (Germany). According to the documents from Catalent Pharma Solutions and Fisher Clinical Services UK Limited, Ukrainian physicians were involved in the experimentation.

Sources include:

GreatGameIndia.com

GreatGameIndia.com